Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153556 · ClinicalTrials.gov registry record · Phase 4
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
A Phase 4 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 4
- Development phase
- 3,200
- Enrollment target
NCT00153556: Completed Phase 4 study, sponsored by Centers for Disease Control and Prevention.
NCT00153556 is a Phase 4 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 3,200 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (518% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00153556, a Phase 4 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3,200 participants
- Enrollment target
Study Summary
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated. This study is designed to test one possible means of eliminating Hib carriage and thus to eliminate person to person transmission and invasive disease. The objective of this study is to evaluate the effectiveness of community-wide use of Hib conjugate vaccine for eliminating oropharyngeal Hib carriage in rural Alaska villages. Secondary objectives include: * Determine risk factors for Hib OP carriage including demographic characteristics, and immunologic characteristics (antibody level and function). This will be accomplished through a case-control study described below. * Measure antibody response to Hib conjugate vaccine among adults who have not previously received Hib vaccine. This will be accomplished through a cohort study of participating adults in the vaccine intervention communities.
Interventions
- BIOLOGICAL Hib conjugate vaccine (HbOC, Wyeth Vaccines)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-11 |
| Phase | Phase 4 |
What the finished NCT00153556 record still lists
NCT00153556 is an interventional study that assigns participants to a tested intervention. Its 3,200 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (518% higher).
The record links to 0 conditions, and to 1 intervention - of which Hib conjugate vaccine (HbOC, Wyeth Vaccines) is the first listed.
NCT00153556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00153556 about?
NCT00153556 is a clinical study titled "Study to Eliminate Hib Carriage in Rural Alaska Native Villages". Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated. This study is designed to test one possible means of eliminating Hib carriage and thus to ...
What is the current status of trial NCT00153556?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3,200 participants. The study started on 2001-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00153556?
The interventions under investigation include: Hib conjugate vaccine (HbOC, Wyeth Vaccines) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00153556?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00153556's enrollment target sits among peer trials
3,200 24th of 2000 higher than 1,976 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
- NCT06042543 · 3,200 participants · NA
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia